Candriam S.C.A. Relay Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
A detailed history of Candriam S.C.A. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 1,092,705 shares of RLAY stock, worth $6.12 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,092,705
Previous 703,429
55.34%
Holding current value
$6.12 Million
Previous $4.59 Million
68.69%
% of portfolio
0.05%
Previous 0.03%
Shares
12 transactions
Others Institutions Holding RLAY
# of Institutions
202Shares Held
156MCall Options Held
207KPut Options Held
40K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$156 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$81 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$59 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.25MShares$51.8 Million5.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.38MShares$41.3 Million0.88% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $673M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...